Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;83(6):489-504.
doi: 10.1002/jdn.10283. Epub 2023 Jun 20.

Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation

Marion Deon  1   2 , Gilian Guerreiro  1   2 , Julia Girardi  3 , Graziela Ribas  2 , Carmen Regla Vargas  1   2   4   5
Affiliations
Review

Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation

Marion Deon et al. Int J Dev Neurosci. 2023 Oct.

Abstract

Maple syrup urine disease (MSUD) is caused by a deficiency in the activity of the branched-chain α-ketoacid dehydrogenase (BCKD) complex, promoting the accumulation of the branched-chain amino acids (BCAA) leucine, isoleucine, and valine, as well as their respective α-keto acids. MSUD is an autosomal recessive hereditary metabolic disorder characterized by ketoacidosis, ataxia, coma, and mental and psychomotor retardation. The mechanisms involved in the brain damage caused by MSUD are not fully understood. Early diagnosis and treatment, as well as proper control of metabolic decompensation crises, are crucial for patients' survival and for a better prognosis. The recommended treatment consists of a high-calorie diet with restricted protein intake and specific formulas containing essential amino acids, except those accumulated in MSUD. This treatment will be maintained throughout life, being adjusted according to the patients' nutritional needs and BCAA concentration. Because dietary treatment may not be sufficient to prevent neurological damage in MSUD patients, other therapeutic strategies have been studied, including liver transplantation. With transplantation, it is possible to obtain an increase of about 10% of the normal BCKD in the body, an amount sufficient to maintain amino acid homeostasis and reduce metabolic decompensation crises. However, the experience related to this practice is very limited when considering the shortage of liver for transplantation and the risks related to the surgical procedure and immunosuppression. Thus, the purpose of this review is to survey the benefits, risks, and challenges of liver transplantation in the treatment of MSUD.

Keywords: branched-chain amino acids; branched-chain α-ketoacid dehydrogenase complex; liver transplant; maple syrup urine disease; treatment.

PubMed Disclaimer

References

REFERENCES

    1. Abaalkhail, F. A., al Sebayel, M. A., Shagrani, M. A., O’Hali, W. A., Almasri, N. M., Alalwan, A. A., Alghamdi, M. Y., al-Bahili, H., AlQahtani, M. S., Alabbad, S. I., al-Hamoudi, W. K., & Alqahtani, S. A. (2021). Clinical practice guidelines for liver transplantation in Saudi Arabia. Saudi Medical Journal, 42(9), 927-968. https://doi.org/10.15537/smj.2021.42.9.20210126
    1. Bahl, J., & Bressler, J. (1989). The pharmacology of carnitine. Pharmacology, 337(1-2), 118-284. https://doi.org/10.1016/0163-7258(89)90067-3
    1. Barschak, A. G., Marchesan, C., Sitta, A., Deon, M., Giugliani, R., Wajner, M., & Vargas, C. R. (2008). Maple syrup urine disease in treated patients: Biochemical and oxidative stress profiles. Clinical Biochemistry, 41(4-5), 317-324. https://doi.org/10.1016/j.clinbiochem.2007.11.015
    1. Barschak, A. G., Sitta, A., Deon, M., de Oliveira, M. H., Haeser, A., Dutra-Filho, C. S., Wajner, M., & Vargas, C. R. (2006). Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metabolic Brain Disease, 21(4), 279-286. https://doi.org/10.1007/s11011-006-9030-5
    1. Berquist, R. K., Berquist, W. E., Esquivel, C. O., Cox, K. L., Wayman, K. I., & Litt, I. F. (2008). Non-adherence to post-transplant care: Prevalence, risk factors and outcomes in adolescent liver transplant recipients. Pediatric Transplantation, 12, 194-200. https://doi.org/10.1111/j.1399-3046.2007